We used two strains of ampicillin-susceptible Escherichia coli to produce meningitis in rabbits and utilized these models (i) to compare the killing effects of parenteral trimethoprim-sulfamethoxazole (TMP-SMZ) and ampicillin on E. coli in cerebrospinal fluid after 8 h oftreatment and (ii) to measure the penetration of TMP-SMZ and ampicillin into cerebrospinal fluid and the brain. At 16 h after intracisternal inoculation with a test strain, rabbits were treated with TMP (6 mg/kg per h) and SMZ (30 mg/kg per h), ampicillin (40 mg/kg per h), or saline intravenously for 8 h. TMP-SMZ levels were measured by high-pressure liquid chromatography, and ampicillin levels were measured by microbiological assay. Mean ± standard deviation concentrations of TMP, SMZ, and ampicillin in cerebrospinal fluid (mean percent penetration) at the completion of 8 h of therapy were 0.80 ± 0.41 (18%), 15.7 ± 12.1 (27.2%), and 2.6 ± 1.7 (8.9%) ,ug/ml, respectively. TMP, SMZ, and ampicillin levels in brain homogenate after 8 h of therapy were 0.23 ± 0.07 (6.6%), 3.31 + 3.3 (5.5%), and 0.6 ± 4.53 (1.9%) ,ug/g, respectively. TMP-SMZ infusion for 8 h produced a significant reduction in mean bacterial counts in cerebrospinal fluid in both models of meningitis compared with saline controls. The decrease in mean bacterial counts with TMP-SMZ therapy was equivalent to that produced by ampicillin.
We used two strains of ampicillin-susceptible Escherichia coli to produce meningitis in rabbits and utilized these models (i) to compare the killing effects of parenteral trimethoprim-sulfamethoxazole (TMP-SMZ) and ampicillin on E. coli in cerebrospinal fluid after 8 h oftreatment and (ii) to measure the penetration of TMP-SMZ and ampicillin into cerebrospinal fluid and the brain. At 16 h after intracisternal inoculation with a test strain, rabbits were treated with TMP (6 mg/kg per h) and SMZ (30 mg/kg per h), ampicillin (40 mg/kg per h), or saline intravenously for 8 h. TMP-SMZ levels were measured by high-pressure liquid chromatography, and ampicillin levels were measured by microbiological assay. Mean ± standard deviation concentrations of TMP, SMZ, and ampicillin in cerebrospinal fluid (mean percent penetration) at the completion of 8 h of therapy were 0.80 ± 0.41 (18%), 15 .7 ± 12.1 (27.2%), and 2.6 ± 1.7 (8.9%) ,ug/ml, respectively. TMP, SMZ, and ampicillin levels in brain homogenate after 8 h of therapy were 0.23 ± 0.07 (6.6%), 3.31 + 3.3 (5.5%), and 0.6 ± 4.53 (1.9%) ,ug/g, respectively. TMP-SMZ infusion for 8 h produced a significant reduction in mean bacterial counts in cerebrospinal fluid in both models of meningitis compared with saline controls. The decrease in mean bacterial counts with TMP-SMZ therapy was equivalent to that produced by ampicillin.
Neonatal meningitis due to aerobic, gram-negative bacilli continues to cause significant morbidity and mortality whether or not parenteral antibiotics are supplemented by intrathecal or intraventricular therapy (15) . Ampicillin with or without an aminoglycoside is currently recommended for therapy of coliform meningitis. But an increasing number of gram-negative bacilli isolated from neonates with meningitis, including Escherichia coli, are resistant to ampicillin (15) . Thus, there is a need to evaluate alternative antimicrobial agents for their effectiveness.
One such agent is trimethoprim-sulfamethoxazole (TMP-SMZ). This antibiotic combination has excellent in vitro activity against aerobic, gram-negative bacilli (1, 2) . At present there are limited data concerning the use of TMP-SMZ in the therapy of either experimental or clinical bacterial meningitis (7, 10, 16, 19, 22, 23) . Kirwan (10) reported the successful treatment of one patient with meningitis given oral TMP-SMZ, and measured blood and cerebrospinal fluid (CSF) levels of TMP and SMZ. There have also been several case reports (7, 16, 22) which describe the successful treatment of meningitis with oral TMP-SMZ, but there was no documentation of blood or CSF levels. Sabel and Brandberg (23) reported the successful treatment with parenteral TMP-SMZ of eight of nine infants with meningitis who were considered therapeutic failures. Finally, Perfect et al. (19) have recently reported the treatment of experimental Haemophilus influenzae type b meningitis in rabbits with parenteral TMP-SMZ. They found that TMP-SMZ was as effective as ampicillin and chloramphenicol in the treatment of this experimental infection. These uncontrolled clinical reports and the animal study lend impetus to further evaluation of parenteral TMP-SMZ in the treatment of bacterial meningitis.
We compared intravenous TMP-SMZ and ampicillin therapy of experimental E. coli meningitis in rabbits. Our goals were: (i) to measure the penetration of TMP-SMZ and ampicillin into the CSF and brain and (ii) to compare the bactericidal effects of TMP-SMZ and ampicillin in the CSF after 8 h of treatment.
(This study was presented in part at the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September, 1980.).
MATERIALS AND METHODS Organisms. The two strains of E. coli, C7K1 (EC7) and C13NK1 (EC13), used for these studies were isolated from neonates with meningitis and kindly provided by George McCracken, University of Texas Health Science Center, Dallas. The organisms were maintained on Mueller-Hinton (MH) agar (Difco Laboratories) at room temperature and subcultured weekly.
Drugs for in vitro studies. TMP (lot no. 089) and SMZ (lot no. 709115) were kindly supplied by Hoffmann-La Roche, Inc., Nutley, N.J. TMP and SMZ were solubilized by a method previously described (18) . TMP was dissolved in 1 ml of methanol; MH broth was added to yield a final concentration of 20 tig/ml. SMZ was dissolved in 0.3 ml of 0.1 N NaOH;
MH broth was added to yield a final concentration of 400 ug/ml. These stock solutions were made every 2 weeks and stored at -20°C. Ampicillin trihydrate was donated by Bristol Laboratories, Inc., Syracuse, N.Y., and was made fresh on the day in vitro tests were performed.
In vitro studies. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of ampicillin and TMP-SMZ were determined by a twofold tube dilution technique in MH broth (27) ; TMP-SMZ was kept at a fixed concentration ratio of 1:20 (wt/wt).
The inoculum was a dilution of an overnight growth of the test strain in MH broth adjusted by nephelometry (Coleman Junior 6A Spectrophotometer, Coleman Instruments, Maywood, Ill.) to contain 105 colony-forming units (CFU) per ml of broth. Thymidine phosphorylase (0.1 IU/ml; Burroughs-Wellcome Co., Research Triangle Park, N.C.) was added to remove any thymidine that may have been present in the broth and that could counteract the antibiotic effects of TMP and SMZ (5) .
The MIC was defined as the lowest concentration of drug(s) which inhibited visible growth after 18 with EC13 meningitis were treated for 8 h with TMP (6 mg/kg per h) and SMZ (30 mg/kg per h); nine rabbits with EC7 meningitis and seven rabbits with EC13 meningitis were treated for 8 h with ampicillin (40 mg/kg per h). No loading doses were given. The doses of TMP-SMZ were chosen because they produced serum and CSF levels in uninfected rabbits that were similar to those reported in humans (9, 10, 26) .
TMP-SMZ was compounded with 10% ethyl alcohol and 1% benzyl alcohol in 5-ml vials and kindly supplied by Hoffmann-La Roche, Inc. TMP-SMZ was diluted with 5% dextrose in water and delivered by continuous intravenous infusion via a peripheral ear vein by using a Harvard infusion-withdrawal pump (model 940; Harvard Apparatus, Millis, Mass.) at a rate of 21.5 ml/h. At this rate no crystallization occurred. Ampicillin was diluted in phosphate-buffered saline and administered by continuous intravenous infusion. Rabbits were restrained by physical means during the infusion, thereby avoiding the negative effects of barbiturate on choroidal CSF production (6) .
A second group of 16 animals, 7 with EC7 meningitis and 9 with EC13 meningitis, received a saline infusion for 8 h and served as infected, untreated controls.
A third group, consisting of two uninfected animals, received TMP-SMZ intravenously for 8 h at the same doses previously noted and served as uninfected controls.
A fourth group of nine rabbits was used to determine the course of untreated EC7 meningitis. These untreated rabbits were followed for a maximum of 96 h post-inoculation or until they died. Cisternal punctures were done on all animals that died. Quantitation of bacteria in CSF was performed on rabbits dying less than 18 h after inoculation. Cultures were done on rabbits dying more than 18 hours after inoculation, but no quantitation was performed because cistemal punctures were not usually done until several hours after death. These cultures are therefore reported only as positive or negative.
Before the initiation of therapy, a cisternal tap was performed, and 0.2 ml of CSF was obtained for quantitative culture. At the end of the 8-h infusion, animals were sacrificed by barbiturate overdose. Blood was obtained by heart puncture, and CSF was obtained by cisternal tap. Samples used for determination of antimicrobial concentration were stored at -20°C until assays were performed. A 0.2-ml sample of CSF was used for quantitation of bacteria. The brain was removed immediately after sacrifice by a technique previously described (3) . Briefly, after a midline incision was made over the skull and skin was retracted, multiple burr holes were placed, and a skull flap was removed. The brain was removed in toto, washed once in phosphate-buffered saline, quick-frozen in an alcohol bath, and stored at -20°C. Samples from uninfected rabbits were taken in a similar fashion.
Quantitation of bacteria. The numbers of E. coli in CSF were determined by plating 0.1-ml samples of undiluted or serial 10-fold dilutions of spinal fluid on MH agar. Colony counts were determined after incubation at 37°C for 24 degassed before use. The flow rate was set at 2.5 ml/ min, and the high-pressure liquid chromatography attenuation was set at 0.01 absorbance units full scale (SMZ-AcSMZ assays) or at 0.005 absorbance units full scale (TMP assay). Figure 1 shows the results of the high-pressure liquid chromatography assay for SMZ-AcSMZ in serum, CSF, and brain. The retention times for SMZ, AcSMZ, and diaveridine were 3.2, 3.8, and 7.0 mi, respectively. Linear calibration plots of peak height ratio (SMZ or AcSMZ to diaveridine) versus concentration were constructed daily by subjecting standard biological samples containing 10 to 115 jg of SMZ and AcSMZ per ml to the assay methodology. TMP and its metabolites, at concentrations as high as 5 icg/ml, did not interfere with SMZ-AcSMZ determinations. In this study SMZ concentrations are equal to nonacetylated SMZ. Figure 2 shows the results of the high-pressure liquid chromatography assay for TMP in serum, CSF, and brain homogenates. The retention times for TMP, the N, and N3 oxides of TMP, a-OH TMP, 3-OH TMP, 4-OH TMP, and diaveridine were 8.8, 6.6, 10.9, 4.1, 4.6, 3.4, and 7.0 min, respectively. Linear calibration plots of peak height ratio (TMP/diaveridine) versus concentration were constructed daily by subjecting standard biological samples containing 0.12 to 1.2 ,ug of TMP per ml to the assay methodology. SMZ and AcSMZ at concentrations as high as 115 ,g/ml did not interfere with the determination of TMP.
The following assay modification was made for CSF samples containing low concentrations of TMP. One hundred microliters of a solution of diaveridine in acetonitrile (0.0625 itg/ml) was evaporated to dryness under nitrogen, and the residue was reconstituted with 250 pl of the CSF sample; 200 ,l of the resultant mixture was injected onto the column.
The mean overall recoveries (n = 16 to 20 ± stan- Antimicrobial levels. Table 2 shows a comparison of TMP and SMZ levels in serum, CSF, and brain in rabbits with and without meningitis at the end of 8 h of treatment. There was no statistical difference in mean serum, CSF, and brain concentrations of TMP and SMZ between rabbits with EC7 and EC13 meningitis. Therefore, these data were pooled and used to calculate the mean concentrations reported in Table  2 .
Mean serum TMP and SMZ concentrations in rabbits with meningitis were similar to those in controls. The mean concentration of TMP in CSF of rabbits with meningitis was greater than that found in the two control rabbits. For most of the rabbits with meningitis there was a twofold or greater increase in CSF TMP levels compared with those in controls. The concentration of SMZ in CSF of rabbits with meningitis showed considerable variability, but the mean level was similar to that of the two controls. Of note are CSF and brain TMP and SMZ concentrations in the two control rabbits that exceeded the MBCs of these drugs for the test strains.
Ampicillin concentrations in serum, CSF, and brain of rabbits with meningitis are also pre- CFU/ml, n = 52).
In rabbits with EC7 meningitis, TMP-SMZ and ampicillin therapy resulted in a significant decrease in the mean concentration of bacteria in CSF when compared with that of controls. The mean decrease in bacterial counts was the same for rabbits treated with TMP-SMZ and ampicillin. In rabbits with EC13 meningitis, TMP-SMZ and ampicillin therapy also resulted in a significant reduction in the mean number of bacteria in CSF compared with that of controls. The difference between these agents in the mean fall of bacterial counts after 8 h of therapy was not statistically significant.
During the 8-h period between 16 and 24 h post-inoculation, control rabbits with EC7 meningitis had a greater mean increase in bacterial counts than did rabbits with EC13 meningitis (2.5 logs versus 0.03 log). This difference occurred despite the fact that the mean bacterial concentration of EC7 in CSF 16 h after inoculation was less than that for EC13.
DISCUSSION
Penetration of TMP-SMZ into CSF and brain. In the absence of meningeal inlanmation, ampicillin, cephalosporins, and aminoglycosides penetrate poorly, if at all, into CSF and the brain (3). In the presence of inflamed meninges, penetration of these agents into CSF increases and is proportional to the severity of infection (4), but may not exceed the MIC for a given pathogen.
In the current study TMP and SMZ concentrations in CSF exceeded the MBCs of both the test strains in the absence of an inflammatory stimulus. CSF concentrations further increased, especially that of TMP, with meningeal inflammation and were similar to those reported in humanxs (10, 26 20, 1981 on January 5, 2018 by guest http://aac.asm.org/
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Whether TMP-SMZ can penetrate into a cerebral abscess and maintain its antibacterial activity in this milieu requires further study.
Penetration of ampicillin into CSF and the brain. There was considerable variability in the ampicillin serum levels as demonstrated by the large standard deviation in Table 2 . Other authors (20, 24, 25) have also noted wide animalto-animal variability of serum levels when antibiotics are administered on the basis of weight. But an individual animal will have minimal fluctuations in the serum level with a constant infusion of drug (3) . Therefore, to miniize variability one can present the data as compartmental ratios (CSF/serum, brain/serum), which has been done in Table 2 .
In a previous study (3) it was shown that there is a 9-to 10-fold increase in the concentration of ampicillin in CSF of rabbits with EC13 meningitis compared to those without meningitis. This resulted in a mean percent penetration into the CSF of 9.7% of the simultaneous serum level. In the present study, mean percent penetration of ampicillin into CSF of rabbits with meningitis was 8.9%. This produced concentrations of ampicillin in CSF which exceeded the MIC for both test strains and correlated with a marked reduction in CSF bacterial counts of EC7 and EC13.
There is minimal information about the penetration of ampicillin or other antibiotics into brain tissue. Kramer et al. (11) have reported on the penetration of several antibiotics, including ampicillin, into normal brain tissue of patients undergoing neurosurgical procedures. In this study, the mean percent penetration of ampicillin into brain tissue was 1.9% after intravenous administration of 2 g of ampicillin. Among four of five patients sampled less than 2 h after the ampicillin injection, no drug could be detected in brain samples.
In the present study the mean percent penetration of ampicillin into brain tissue of rabbits with meningitis was 1.9% at the completion of an 8-h continuous infusion. One cannot directly compare the results of these studies because of differences in dose, method of administration, half-life, and methods for determining ampicillin concentration. Data in the present study reveal minimal penetration of ampicillin into brain tissue of rabbits in the presence of meningitis. Whether the concentration of ampicillin would be increased further in the presence of parenchymal brain infection and the drug would maintain its antibacterial activity requires further study.
Therapy of meningitis. In rabbits with EC7 and EC13 meningitis, therapy with TMP-SMZ for 8 h reduced the concentration of bacteria in CSF the same extent as ampicillin therapy for 8 h. This was expected based on the in vitro data and the degree of penetration of these agents into the CSF of rabbits with meningitis. Since all animals were sacrificed after 8 h of treatment, the possibility that either of these regimens would result in cure of the meningitis could not be determined in this study. Nonetheless, the rapid reduction in bacterial counts in CSF demonstrated in this study after only 8 h of therapy may be important for the successful therapy of bacterial meningitis (14) .
During the 8-h period between 16 and 24 h post-inoculation, the mean bacterial concentration in the CSF of animals given saline increased by 2.5 logs for EC7 but by only 0.03 log for EC13. The reason for this difference in growth during this period is not clear. The mean concentration of EC13 in CSF was greater than that of EC7 at 16 h post-inoculation but this difference was not statistically significant. The initial inoculum for both strains was also the same. One possible explanation is that the EC7 strain, unlike the EC13 strain, contains the Kl antigen. This antigen has been said to confer increased virulence (28). However, Kl antigen had no implications for survival since the mean duration of survival for untreated rabbits with EC7 and EC13 meningitis was similar (55 h versus 61 h).
These results can be extrapolated to the clinical setting only with great caution. First, a large inoculum is required to produce a lethal infection in this model of meningitis. Second, the route of infection and pathogenesis differ from meningitis which occurs in humans. Third, the impact of preexisting host defenses has not been analyzed in these studies.
In conclusion, TMP and SMZ given parenterally penetrated well into CSF and the brain in the presence or absence of meningeal inflammation in rabbits. In two models of ampicillinsusceptible E. coli meningitis, continuous intravenous TMP-SMZ therapy produced bacterial killing in CSF equivalent to that of ampicillin. These findings suggest a potential therapeutic role for parenteral TMP-SMZ in the treatment of E. coli meningitis and possibly for meningitis caused by other susceptible bacteria, including ampicillin-resistant organisms.
